The estimated Net Worth of Gavin Wood is at least 681 千$ dollars as of 20 May 2022. Mr Wood owns over 39,000 units of Adaptimmune Therapeutics Plc stock worth over 103,680$ and over the last 5 years he sold ADAP stock worth over 0$. In addition, he makes 577,643$ as Chief Financial Officer at Adaptimmune Therapeutics Plc.
Mr has made over 3 trades of the Adaptimmune Therapeutics Plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 39,000 units of ADAP stock worth 11,310$ on 20 May 2022.
The largest trade he's ever made was buying 39,000 units of Adaptimmune Therapeutics Plc stock on 20 May 2022 worth over 11,310$. On average, Mr trades about 12,000 units every 86 days since 2020. As of 20 May 2022 he still owns at least 96,000 units of Adaptimmune Therapeutics Plc stock.
You can see the complete history of Mr Wood stock trades at the bottom of the page.
Gavin Hilary James Wood BA (Hons), ACA is the Chief Financial Officer at Adaptimmune Therapeutics Plc.
As the Chief Financial Officer of Adaptimmune Therapeutics Plc, the total compensation of Mr ACA at Adaptimmune Therapeutics Plc is 577,643$. There are 7 executives at Adaptimmune Therapeutics Plc getting paid more, with James Noble having the highest compensation of 2,821,740$.
Mr ACA is 51, he's been the Chief Financial Officer of Adaptimmune Therapeutics Plc since . There are 14 older and 4 younger executives at Adaptimmune Therapeutics Plc. The oldest executive at Adaptimmune Therapeutics Plc is Lawrence Alleva, 70, who is the Non-Executive Independent Director.
Gavin's mailing address filed with the SEC is C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, X0, OX14 4RX.
Over the last 9 years, insiders at Adaptimmune Therapeutics Plc have traded over 40,532,026$ worth of Adaptimmune Therapeutics Plc stock and bought 384,338,252 units worth 527,131,726$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, Adaptimmune Therapeutics Plc executives and independent directors trade stock every 20 days with the average trade being worth of 2,827,332$. The most recent stock trade was executed by Cintia Piccina on 18 June 2024, trading 24,531 units of ADAP stock currently worth 22,814$.
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Adaptimmune Therapeutics Plc executives and other stock owners filed with the SEC include: